A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants

NCT07432698 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: AK0406 150 mg
DRUG: AK0406 300 mg
DRUG: AK0406 600 mg
DRUG: AK0406 900 mg
DRUG: 0.9% Sodium Chloride Injection as Placebo

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.

Collaborators

[object Object]